Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington
Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )
26 Feb 2025

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA
Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )
25 Feb 2025

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France
SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )
19 Feb 2025

Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia

Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia
Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia ( Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia )
13 Feb 2025

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )
14 Jan 2025

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results

Prof Salomon Manier - Hospital Center University De Lille, Lille, France
Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )
9 Jan 2025

SABCS 2024: Highlights in breast cancer genomic testing

Prof Matteo Lambertini and Prof Virginia Kaklamani
SABCS 2024: Highlights in breast cancer genomic testing ( Prof Matteo Lambertini and Prof Virginia Kaklamani )
23 Dec 2024

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )
20 Dec 2024

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2024

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2024

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA
Glofitamab with rituximab, ifosfamide, carboplatin  and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )
18 Dec 2024

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )
17 Dec 2024